The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world data of TAS-102 therapy in refractory metastatic colorectal cancer (mCRC): The experience of the University Hospital of Montreal (CHUM).
 
Reem El Khoury
No Relationships to Disclose
 
Jad Tehfe
No Relationships to Disclose
 
Marie Ouellet
No Relationships to Disclose
 
Francine Aubin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Canada; Incyte; Merck; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bristol-Myers Squibb Canada; Merck; Pfizer; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb/Medarex (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst)
 
Rasmy Lougnarath
No Relationships to Disclose
 
Jean-Pierre M. Ayoub
Honoraria - AstraZeneca; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Novartis; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca Canada; Gilead Sciences; Knight Therapeutics; Lilly; Merck; Novartis; Pfizer; Seagen
Speakers' Bureau - AstraZeneca Canada; Knight Therapeutics; Merck; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca Canada (Inst); Immunomedics (Inst); Seagen (Inst)
 
Mustapha Tehfe
Honoraria - Bristol-Myers Squibb; Merck; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical
Research Funding - Pfizer Hellas (Inst); Taiho Pharmaceutical (Inst)